Applied therapeutics inc. (APLT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
OPERATING EXPENSES:
Research and development

7,271

13,769

7,453

4,254

6,874

5,360

2,726

1,937

1,448

General and administrative

5,196

3,900

3,294

4,183

1,855

629

598

400

420

Total operating expenses

12,467

17,669

10,747

8,437

8,729

5,989

3,324

2,337

1,868

LOSS FROM OPERATIONS

-12,467

-17,669

-10,747

-8,437

-8,729

-5,989

-3,324

-2,337

-1,868

OTHER INCOME (EXPENSE), NET:
Interest income (expense), net

122

60

34

0

-1

-244

-584

-533

-281

Other income (expense)

-24

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

373

315

186

Total other income (expense), net

98

36

34

0

-1

-731

-957

-848

-467

Net loss

-12,369

-17,633

-10,713

-8,437

-8,730

-6,720

-4,281

-3,185

-2,335

Net loss attributable to common stockholders—basic

-12,369

-17,633

-10,713

-8,437

-8,730

-6,720

-4,281

-3,185

-2,335

Net loss attributable to common stockholders— diluted

-12,369

-

-10,713

-

-8,730

-

-4,281

-

-2,335

Net loss per share attributable to common stockholders—basic and diluted

-0.59

-0.74

-0.63

-0.60

-1.58

-1.22

-0.78

-0.58

-0.43

Weighted-average common stock outstanding—basic and diluted

20,840

14,769

17,095

13,945

5,513

5,512

5,497

5,463

5,458